Infinity Pharmaceuticals Provides Additional Information On MARIO-8 Study Evaluating Eganelisib In Combination With The PD-1 Targeted Checkpoint Inhibitor Pembrolizumab In Patients With Squamous Cell Cancer Of The Head And Neck
Portfolio Pulse from Happy Mohamed
Infinity Pharmaceuticals (NASDAQ:INFI) has provided further details on its Phase 2 MARIO-8 study evaluating eganelisib in combination with pembrolizumab in patients with squamous cell cancer of the head and neck. The adaptive design of the study aims to optimize the dose of eganelisib. Preliminary safety and efficacy data are expected in the second half of 2024. The company is also progressing towards a merger with MEI Pharma, which has been recommended by two leading independent proxy advisory firms.
July 10, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Infinity Pharmaceuticals is progressing with its MARIO-8 study and a merger with MEI Pharma. Both developments could potentially impact the company's stock positively.
The progress in the MARIO-8 study and the potential merger with MEI Pharma are significant developments for Infinity Pharmaceuticals. If successful, both could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100